Melanotan I vs Melanotan II: The Science and Risks
Melanotan and Melanocortin Tanning
5 melanocortin receptors
Melanotan I selectively targets MC1R for pigmentation. Melanotan II activates all five melanocortin receptor subtypes, producing tanning, appetite suppression, and sexual arousal.
Bohm et al., JEADV, 2025
Bohm et al., JEADV, 2025
View as imageMelanotan I and melanotan II are both synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous peptide that triggers melanin production in skin. Both were developed at the University of Arizona in the 1980s and 1990s as research tools to study pigmentation. Despite their similar names, they differ in structure, receptor selectivity, approved uses, safety profiles, and legal status. Melanotan I went on to become afamelanotide (Scenesse), an FDA-approved drug for a rare disease. Melanotan II became a widely circulated unregulated tanning and sexual enhancement product sold through grey-market channels. Understanding the distinction between these two peptides requires understanding the melanocortin receptor system they both act on, and why activating one receptor versus five produces very different outcomes.
Key Takeaways
- Melanotan I (afamelanotide) is a linear 13-amino-acid peptide with high selectivity for MC1R, the receptor specifically responsible for skin pigmentation and DNA repair (Bohm et al., JEADV, 2025)
- Melanotan II is a cyclic 7-amino-acid peptide that activates MC1R, MC3R, MC4R, and MC5R, producing tanning, appetite suppression, sexual arousal, and cardiovascular effects
- Afamelanotide (melanotan I) received FDA approval in 2019 for erythropoietic protoporphyria, with long-term safety data showing biopsied moles were all benign (Bohm et al., JEADV, 2025)
- A 22-year-old female developed oral mucosal malignant melanoma after using melanotan II nasal spray for tanning (Yassin Alsabbagh et al., Int J Oral Maxillofac Surg, 2025)
- Melanotan II is illegal to sell in the UK, US, and Australia; it has no standardized manufacturing, no clinical trial program, and no long-term safety monitoring
- The melanocortin system has produced three FDA-approved drugs from alpha-MSH analogs: afamelanotide, bremelanotide, and setmelanotide, each targeting different receptor subtypes for different conditions
The Melanocortin Receptor System
Both melanotan peptides work through the melanocortin receptor family, a group of five G protein-coupled receptors (MC1R through MC5R) that regulate diverse biological functions. For a full overview of how alpha-MSH controls skin pigment through this receptor system, see the dedicated article. The key to understanding why melanotan I and II behave so differently lies in which receptors each peptide activates.[1]
| Receptor | Primary Function | Location |
|---|---|---|
| MC1R | Skin pigmentation, DNA repair, eumelanin synthesis | Melanocytes, immune cells |
| MC2R | Cortisol production (ACTH receptor) | Adrenal cortex |
| MC3R | Energy homeostasis, inflammation | Brain, gut, immune cells |
| MC4R | Appetite regulation, sexual function, blood pressure | Hypothalamus, brainstem |
| MC5R | Sebaceous gland function, immune modulation | Exocrine glands, skin |
Melanotan I binds preferentially to MC1R, the receptor that directly controls melanin production. Melanotan II binds to MC1R, MC3R, MC4R, and MC5R with varying affinities. This broad receptor profile explains why melanotan II produces a constellation of effects beyond tanning: MC4R activation suppresses appetite and triggers sexual arousal, MC3R activation alters energy metabolism, and the combined stimulation of multiple receptors produces the nausea, facial flushing, and yawning commonly reported by users.
Melanotan I: Structure and Development
Melanotan I (now known by its International Nonproprietary Name afamelanotide) is a linear peptide of 13 amino acids. It differs from endogenous alpha-MSH at two positions: norleucine replaces methionine at position 4, and D-phenylalanine replaces L-phenylalanine at position 7. These substitutions increase metabolic stability and extend the peptide's half-life while preserving MC1R selectivity.[2]
The MC1R selectivity is what makes afamelanotide a viable pharmaceutical product. By confining its effects largely to melanocytes, it produces skin pigmentation and genuine photoprotection through eumelanin synthesis and DNA repair upregulation without the cardiovascular, appetite, and sexual side effects of broader melanocortin activation.[1]
Afamelanotide received FDA approval in October 2019 for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder in which patients experience severe phototoxic pain from sunlight exposure. It is administered as a 16 mg subcutaneous implant that slowly releases the peptide over approximately 60 days. In clinical trials, EPP patients receiving afamelanotide spent more time in sunlight with less pain and fewer phototoxic reactions. Long-term safety data from EPP patients, including biopsied moles that all proved benign, provides the strongest evidence that selective MC1R activation does not inherently promote melanoma.[1]
Al Musaimi's 2024 review of FDA-approved peptide analogs traced the developmental pathway from alpha-MSH to afamelanotide, noting how targeted amino acid substitutions created a drug with a defined therapeutic window and acceptable risk profile.[3]
Melanotan II: Structure and Black Market Reality
Melanotan II is a cyclic heptapeptide (7 amino acids) with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Its cyclic structure and shorter length give it a different receptor binding profile than melanotan I. While it still activates MC1R to produce tanning, it also has strong activity at MC4R (appetite and sexual function) and MC3R (energy homeostasis).
Melanotan II was never completed through clinical development for any indication. It has no FDA approval, no EMA approval, and no standardized manufacturing. The peptide circulates through online vendors, grey-market peptide suppliers, and social media channels, sold as a tanning aid or sexual enhancer. Users self-administer it by subcutaneous injection or nasal spray, typically without medical supervision.
The lack of quality control is a fundamental problem. Stability analysis of alpha-MSH analogs shows these peptides degrade under heat, light, oxidative stress, and pH changes, producing degradation products that may lack efficacy or pose unknown safety risks.[2] Products purchased online have no assurance of purity, accurate concentration, or absence of contaminants.
The Melanoma Question
The relationship between melanotan II and melanoma risk is the most debated safety concern. Several case reports have documented melanoma in melanotan II users, but establishing causation is complicated by confounding factors.
A 2025 case report described a 22-year-old female who developed oral mucosal malignant melanoma after using melanotan II nasal spray for tanning. The tumor was located in the anterior maxilla. She underwent surgical resection followed by immunotherapy.[4] Oral mucosal melanoma is exceedingly rare in a 22-year-old, making the temporal association with melanotan II use noteworthy. Other published cases include melanoma developing on existing nevi after melanotan II use.
The confounding variable is UV exposure. Melanotan II users are, by definition, people seeking a tan. They frequently combine the peptide with sunbed use or intensive sun exposure. UV radiation is the single strongest environmental risk factor for melanoma. A 2021 review concluded that increased melanoma risk in melanotan users could probably be explained by more UV exposure rather than the peptide itself. But this does not rule out a synergistic effect: stimulating melanocyte proliferation with melanotan II while simultaneously exposing those cells to UV-induced DNA damage could theoretically accelerate malignant transformation.
Bohm and colleagues noted in their 2025 review that MC1R activation through afamelanotide (melanotan I) may actually reduce melanoma risk by promoting eumelanin synthesis and enhancing DNA repair. Eumelanin is the brown/black pigment that absorbs UV radiation and protects DNA, unlike pheomelanin (the red/yellow pigment), which generates reactive oxygen species under UV exposure. Afamelanotide shifts the eumelanin-to-pheomelanin ratio favorably. Whether melanotan II produces the same protective shift is unknown, because its broad receptor activity adds variables that have not been systematically studied.[1]
Side Effects: A Tale of Two Profiles
Melanotan I (Afamelanotide)
Side effects in clinical trials were limited and mostly related to the implant procedure: injection site reactions, headache, and darkening of pre-existing nevi (which were biopsied and found benign). The MC1R selectivity keeps afamelanotide's effects largely confined to the skin. No cardiovascular, sexual, or appetite-related side effects have been reported in clinical trial or post-marketing data.[1]
Melanotan II
Melanotan II side effects reflect its broad receptor activation:
- Nausea and facial flushing (common, often dose-dependent)
- Spontaneous erections and increased sexual arousal (MC4R activation)
- Decreased appetite (MC4R activation)
- Fatigue and yawning (central nervous system effects)
- Increased and darkened moles (melanocyte stimulation)
- Priapism (reported in case series, requiring emergency treatment)
- Rhabdomyolysis (documented in a case report of systemic toxicity)
- Renal infarction (potentially fatal, reported in at least one case)
The sexual side effects of melanotan II are directly related to MC4R activation, the same mechanism that underlies bremelanotide (Vyleesi), the FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women. Bremelanotide is itself derived from melanotan II research. The key difference is that bremelanotide underwent rigorous clinical testing to establish safe dosing, while melanotan II users self-dose without medical guidance. Even bremelanotide's clinical data has been scrutinized: Spielmans and Ellefson's 2024 analysis found that the drug's benefits for sexual desire were statistically modest and relied on outcome measures with questionable validity.[5]
The Melanocortin Drug Family
Understanding melanotan I and II in context requires recognizing that three FDA-approved drugs have emerged from alpha-MSH analog research:
Afamelanotide (Scenesse) targets MC1R for erythropoietic protoporphyria. It is also being investigated as a potential chemoprevention strategy for skin cancer in high-risk individuals.[1]
Bremelanotide (Vyleesi) targets MC4R for hypoactive sexual desire disorder. It was approved in 2019, though its clinical benefit is considered modest.[5][6]
Setmelanotide (Imcivree) targets MC4R for rare genetic obesity disorders (POMC, PCSK1, and LEPR deficiency). It is the most selective MC4R agonist in clinical use.
These three drugs illustrate how the melanocortin system can be therapeutically exploited when receptor selectivity is engineered into the peptide. Melanotan II's problem is that it activates the system without selectivity, producing a grab bag of effects with no controlled dosing or safety monitoring.
Barakeh and colleagues' 2025 review of HSDD pharmacotherapy noted that while bremelanotide represents a rational pharmacological approach to melanocortin-mediated sexual desire, its limited efficacy and potential adverse effects, including nausea (40%) and blood pressure changes, warrant caution.[7]
Legal Status and Regulatory Landscape
The legal and regulatory situation for these two peptides could not be more different:
Melanotan I (afamelanotide) is a licensed pharmaceutical product (Scenesse) available by prescription for EPP in the US, EU, and Australia. It is manufactured under GMP conditions with quality control at every stage. Its use outside EPP is off-label.
Melanotan II is not approved for any indication in any country. It is illegal to sell in the UK (classified by MHRA as an unlicensed medicine), subject to consumer warnings from the Australian TGA, and not regulated as an approved drug by the FDA. Despite this, it remains widely available online, often marketed as a "research chemical" to circumvent regulations.
The disconnect between regulatory status and availability makes melanotan II a unique case in the peptide landscape. Unlike most unapproved peptides that remain confined to research settings, melanotan II has penetrated consumer markets through social media promotion, fitness communities, and cosmetic culture.
Head-to-Head Comparison
| Feature | Melanotan I (Afamelanotide) | Melanotan II |
|---|---|---|
| Structure | Linear, 13 amino acids | Cyclic, 7 amino acids |
| Receptor selectivity | MC1R (selective) | MC1R, MC3R, MC4R, MC5R (nonselective) |
| Primary effect | Skin pigmentation, photoprotection | Tanning + appetite + sexual arousal |
| FDA approval | Yes (2019, for EPP) | No |
| Clinical trial data | Phase 2/3 trials, long-term safety data | No completed clinical program |
| Manufacturing | GMP pharmaceutical production | Unregulated, variable quality |
| Administration | 16 mg subcutaneous implant | Self-injection or nasal spray |
| Melanoma risk | Long-term data shows no increased risk | Case reports of melanoma in users |
| Sexual side effects | None reported | Common (MC4R activation) |
| Half-life | Longer (linear structure, slow-release implant) | Shorter (cyclic structure) |
The Bottom Line
Melanotan I and melanotan II share a common origin in alpha-MSH analog research but diverged into fundamentally different products. Melanotan I became afamelanotide, a selective MC1R agonist with FDA approval, GMP manufacturing, clinical trial data, and a safety profile that includes no reported melanoma cases in long-term monitoring. Melanotan II remained an unregulated, nonselective melanocortin agonist distributed through grey-market channels, with case reports of melanoma, priapism, rhabdomyolysis, and renal infarction. The melanocortin receptor system has proven therapeutically valuable when targeted with precision; melanotan II represents what happens when that precision is absent.